THC.ASX
THC Global reveals major strategic changes as part of broader shift into healthcare and pharmaceuticals
Medicinal cannabis company THC Global (ASX: THC) has revealed several major strategic shifts to carve a bigger slice of the wider healthcare and pharmaceutical markets including a rebranding to reflect the move. As part of the rebrand, THC will be renamed Epsilon Healthcare. Shareholders will be required to approve the change at an extraordinary general […]
THC Global signs cannabis medicine production deal with local cultivator Cannatrek
THC Global Group (ASX: THC) has signed a 12-month supply and production deal with Australian “seed-to-patient” medical cannabis business Cannatrek to develop and manufacture Cannatrek-branded medicines on contract. Under the terms of the agreement, Cannatrek will provide dried cannabis flower to THC for production of oil-based medical cannabis marketed under the Cannatrek brand. It will […]
THC Global releases first locally-made medicinal cannabidiol for Australian patients
The first Australian-produced full-spectrum medicinal cannabidiol manufactured by diversified cannabis company THC Global (ASX: THC) has become available for prescription to Australian patients under the country’s Special Access Scheme. Marketed under THC’s flagship Canndeo brand, the medicine has been developed entirely in Australia using cannabis sourced from THC’s Bundaberg cultivation facility in Queensland. It was […]
THC Global to acquire Tetra Health network of medicinal cannabis clinics
THC Global Group (ASX: THC) will pay $3 million in shares and cash to acquire the Tetra Health network of clinics which provide access to legal medicinal cannabis. Tetra’s network comprises over 630 referring and prescribing physicians, as well as dispensing pharmacies across Australia. It generates revenue primarily from consultation fees charged to over 1,100 […]